Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
JAK inhibitors Transcript
So, we've been working on this class of drugs [JAK inhibitors] now for about 5 or 6 years, both in our research...